Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.81 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.81 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180426 | 0.90 | PTGDR2 (0.68) | PTGDR2PTGDRCYSLTR2CYSLTR1PTGIR | |
| SCHEMBL3176547 | 0.90 | PTGDR2 (1.00) | PTGDR2PTGDRCYSLTR2CYSLTR1PTGIR | |
| SCHEMBL3159621 | 0.89 | PTGDR2 (0.72) | PTGDR2PTGDRCYSLTR2CYSLTR1PTGIR | |
| SCHEMBL3169657 | 0.88 | PTGDR2 (0.80) | PTGDR2PTGDRPTGIRHPGDMAPT | |
| SCHEMBL3165589 | 0.88 | PTGDR2 (0.65) | PTGDR2PTGDRCYSLTR2CYSLTR1HPGD | |
| SCHEMBL16493797 | 0.84 | PTGDR2 (0.66) | PTGDR2PTGDRPTGIRHPGDMAPT | |
| SCHEMBL3174685 | 0.83 | PTGDR2 (0.73) | PTGDR2PTGDRPTGIRFFAR1FFAR4 | |
| SCHEMBL3166216 | 0.83 | PTGDR2 (0.86) | PTGDR2PTGDRCYSLTR2CYSLTR1PTGIR | |
| SCHEMBL16493796 | 0.83 | PTGDR2 (0.64) | PTGDR2PTGDRPTGIRHPGDMAPT | |
| SCHEMBL12678564 | 0.80 | PTGDR2 (0.82) | PTGDR2PTGDRCYSLTR2CYSLTR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | claimed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | claimed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | claimed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PTGDR 189/4885CYSLTR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.